Compare · CV vs SLNO
CV vs SLNO
Side-by-side comparison of CapsoVision Inc. (CV) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 8.5x CV ($324.3M).
- Over the past year, CV is up 51.8% and SLNO is down 37.9% - CV leads by 89.7 points.
- CV has hit the wire 3 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- Soleno Therapeutics Inc.
- Price
- $6.55-0.46%
- $53.02+0.08%
- Market cap
- $324.3M
- $2.76B
- 1M return
- -7.88%
- +0.76%
- 1Y return
- +51.80%
- -37.87%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2014
- News (4w)
- 3
- 0
- Recent ratings
- 2
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest CV
- Large owner Harari Eliyahou Et Al bought $410,988 worth of shares (61,068 units at $6.73) (SEC Form 4)
- Large owner Harari Eliyahou Et Al bought $495,117 worth of shares (81,300 units at $6.09) (SEC Form 4)
- Large owner Harari Eliyahou Et Al bought $101,811 worth of shares (13,850 units at $7.35) (SEC Form 4)
- SEC Form 4 filed by Director Shields David Stanley
- New insider Shields David Stanley claimed no ownership of stock in the company (SEC Form 3)
- CapsoVision Inc. filed SEC Form 8-K: Regulation FD Disclosure
- CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
- Director Imperial Joanne Carol exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 120% to 3,709 units (SEC Form 4)
- Amendment: Director Imperial Joanne Carol sold $8,587 worth of shares (1,200 units at $7.16), decreasing direct ownership by 42% to 1,687 units (SEC Form 4)
- Director Tsai Chen Lung exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 70% to 4,929 units (SEC Form 4)
Latest SLNO
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)